RC(SZ:300596) 光大证券研究·2025-10-21 23:07Core Viewpoint - The company reported a revenue of 4.509 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 5.72%, and a net profit attributable to shareholders of 392 million yuan, up 24.92% year-on-year [4]. Financial Performance - In Q3 2025, the company achieved a revenue of 1.514 billion yuan, representing a year-on-year increase of 4.77% and a slight quarter-on-quarter growth of 0.01% [4]. - The net profit attributable to shareholders for Q3 2025 was 151 million yuan, showing a significant year-on-year growth of 60.83% and a quarter-on-quarter increase of 13.17% [4]. - The gross margin for Q3 2025 was 21.97%, which is an increase of 1.37 percentage points year-on-year and 0.32 percentage points quarter-on-quarter [5]. Cost Management - The company reduced its sales, management, and R&D expenses in Q3 2025 by 0.45%, 17.37%, and 37.95% respectively, while financial expenses increased by 62.09% mainly due to exchange rate fluctuations [5]. - The operating expense ratio for Q3 2025 was 10.48%, down 2.25 percentage points year-on-year and 1.37 percentage points quarter-on-quarter [5]. Cash Flow - The net cash inflow from operating activities in Q3 2025 reached 339 million yuan, marking the highest quarterly operating cash flow in the company's history, indicating continuous improvement in operational conditions [5]. Strategic Developments - The company is a leading player in the anti-aging agent industry with six production bases across China and plans to invest in an overseas R&D and production base in Malaysia to enhance its market position [6]. - In the lubricating oil additive sector, the company is actively involved in setting standards and collaborating with major international and domestic firms, aiming to increase the sales proportion of its lubricating oil additive compounds [6]. - The life sciences segment has seen monthly sales surpassing one million yuan, with some products transitioning from pilot to mass production [6]. - The company is also expanding its PI business with dual R&D centers and production bases, with a new facility in Yixing expected to begin trial production in 2026 [6].